Research - TCH - Medical Oncology - Clinical trials
Symptom Benefit: Does Palliative Chemotherapy Improve Symptoms in Women with Recurrent Ovarian Cancer? Measuring subjective improvement as well as objective response to estimate the benefit of palliative chemotherapy in women with platinum resistant or refractory ovarian cancer (ANZGOG-0701/GCIG)
PARAGON – A phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent / metastatic gynaecological neoplasms
Tnacity: A Phase 2/3, multi-centre, open-label, randomized study of weekly nab-paclitaxel in combination with Gemcitabine or carboplatin, compared to Gemcitabine/carboplatin, as first-line treatment in subjects with ER, PgR, and HER2 negative (triple negative) metastatic breast cancer
TRACC:Prospective Study of clinical outcomes and analysis of bevacizumab use in metastatic colorectal cancer: BioGrid Project
APACT:A Phase 3, Multicentre, Open-Label, Randomised study of NAB®-Paclitaxel plus Gemcitabine versus Gemcitabine alone as adjuvant therapy in Subjects with surgically resected pancreatic Adenocarcinoma
JANUS-1: A Randomized, Double-blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination with Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy
AFFINITY: A randomised Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-line Chemotherapy in Men with Metastatic Castrate Resistant Prostate Cancer
EVEREXES: A phase IIIb, multi-centre, open-label, expanded access study of Everolimus (RAD001) in combination with Exemestane in post-menopausal women with estrogen receptor positive, human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer
Mitotane: Mitotane Pharmacodynamics in Adrenocortical Cancer in Children and Adults
PROSPER: A Phase 4, Randomized, Double-Blind, Placebo Controlled Study of Continued Enzalutamide Treatment beyond Progression in Patients with Chemotherapy-Naïve, Metastatic-Castration Resistant Prostate Cancer:
ICON 8:An international phase III randomised trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer
Meki-012:A Phase II Randomised Double Blind Placebo Controlled Trial of Combination of Pimasertib with SAR245409 or of Pimarsertib with SAR245409 Placebo in subjects with Previously Treated Unresectable Low Grade Ovarian Cancer
P3BEP:A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for participants with intermediate and poor-risk metastatic germ cell tumours
IMAGE :A MultiNational, Prospective, Observational Study in Patients with Unresectable or Metastatic Melanoma
DESCRIBE II: Dabrafenib – Trametinib Combination Metastatic Melanoma Named Patient Programme Restrospective Chart Review.
Finding My Way :Coping with Cancer Online: Research Study
Coping Together :A study to help couples manage a recent cancer diagnosis
Clinical Research Staff
A/Professor Desmond Yip, Director, Medical Oncology Research Unit
Olive Doig, RN, Clinical Trials Manager.
Anne Ryan, RN, Clinical Trials Coordinator
Jody Berry, RN, Clinical Trials Coordinator
Edward Craft, Administrative Assistant
Phone (02) 6244 3688.
Dr Christine Hemmings RGON, BHB, MBChB, FRCPA, St John of God Pathology, Subiaco WA.
Dr Alesia Ivashkevich, MSc, PhD, Cancer Research Laboratory, Department of Radiation Oncology, Canberra Hospital.
Dr Anneke Blackburn, BSc PhD, John Curtin School of Medical Research
A/Professor Sudha Rao, BSc PhD, Molecular and Cellular Biology, Centre for Resesarch in Therapeutics Solutions, University of Canberra
A/Professor Kate Pumpa,BSc MSc PhD, Sport and Exercise Science, Faculty of Health, University of Canberra.
Professor Afaf Girgis, Translation Cancer Research Centre, Ingham Insitute for Applied Medical Research, University of NSW.
Research Grants Held
Prof R. Stuart-Harris. Prospective evaluation of cognitive impairment in women receiving adjuvant chemotherapy for early breast cancer. The Canberra Region Medical Foundation
Stuart-Harris R. The Development of a Clinical Palliative Index for the Treatment of Advanced Cancer. The Private Practice Fund, The Canberra Hospital
Stuart-Harris R. Coping Styles and Severity of Toxicity from Adjuvant Chemotherapy for Early Breast Cancer or Colorectal Cancer. Cancer Council ACT.
Yip D. A Cancer Clinical Trials Research Programme in the ACT. Cancer Council ACT.
Yip D, Budge M, Taupin D, Nolan C. Installation and implementation of Bio21:MMIM (Molecular Medicine Informatics Model now known as BioGrid Australia) in Canberra. TCH Radiation Oncology Private Practice Trust Fund.
Haydon A, Zalcberg J, Walpole E, Yip D, Price T, Howard K, Jefford M. Short Course Oncology Therapy- A study of Adjuvant Chemotherapy in Colorectal Cancer by the CACTUS and OCTO Groups. Cancer Australia Priority driven Collaborative Cancer Research Scheme.
Yip D, Dahlstrom J, Jain S, Barry P, Carpenter J, Clarke C. Westmead Millenium Institute, University of Sydney. The Breast Cancer Tissue Bank: establishment of collection site for collection, storage and transfer of human blood and tissue samples in the ACT.